Chun-Hua Xu1,2, Lan Cao2, Ying Wei2, Li-Ke Yu1,2. 1. Department of Respiratory Medicine, Nanjing Chest Hospital, Nanjing, Jiangsu - PR China. 2. Clinical Center of Nanjing Respiratory Diseases and Imaging, Nanjing, Jiangsu - PR China.
Abstract
BACKGROUND: Cripto-1 (CR-1) plays an important role in angiogenesis related to tumor growth, in concert with vascular endothelial growth factor (VEGF), and enhanced expression of CR-1 has been reported in lung cancer tissue. METHODS: Patients with lung cancer (n = 156) and healthy volunteers (n = 60) were enrolled in the study. Serum CR-1 and VEGF concentrations were measured using enzyme-linked immunosorbent assay. RESULTS: Patients with lung cancer had higher serum CR-1 (4.03 ± 1.49 ng/mL vs. 1.13 ± 0.43 ng/mL, p<0.05) and VEGF (503.62 ± 112.74 pg/mL vs. 398.62 ± 117.84 pg/mL, p<0.05) levels than the control group. With stage progression in non-small cell lung cancer (NSCLC), serum CR-1 levels increased, and patients with distant metastasis had higher levels than those without metastasis (p<0.05). In NSCLC, the low CR-1 group (<1.54 ng/mL) had a better overall survival rate compared with the high CR-1 group (>1.54 ng/mL, p<0.05). CONCLUSIONS: Our study suggests that serum CR-1 is a useful diagnostic and prognostic marker for NSCLC patients.
BACKGROUND: Cripto-1 (CR-1) plays an important role in angiogenesis related to tumor growth, in concert with vascular endothelial growth factor (VEGF), and enhanced expression of CR-1 has been reported in lung cancer tissue. METHODS:Patients with lung cancer (n = 156) and healthy volunteers (n = 60) were enrolled in the study. Serum CR-1 and VEGF concentrations were measured using enzyme-linked immunosorbent assay. RESULTS:Patients with lung cancer had higher serum CR-1 (4.03 ± 1.49 ng/mL vs. 1.13 ± 0.43 ng/mL, p&lt;0.05) and VEGF (503.62 ± 112.74 pg/mL vs. 398.62 ± 117.84 pg/mL, p&lt;0.05) levels than the control group. With stage progression in non-small cell lung cancer (NSCLC), serum CR-1 levels increased, and patients with distant metastasis had higher levels than those without metastasis (p&lt;0.05). In NSCLC, the low CR-1 group (&lt;1.54 ng/mL) had a better overall survival rate compared with the high CR-1 group (&gt;1.54 ng/mL, p&lt;0.05). CONCLUSIONS: Our study suggests that serum CR-1 is a useful diagnostic and prognostic marker for NSCLCpatients.
Authors: Leorik Pereira Silva; Luiz Arthur Barbosa da Silva; Bruno Tavares Sedassari; Suzana Cantanhede Orsini Machado de Sousa; Joabe Dos Santos Pereira; Lélia Batista de Souza; Márcia Cristina da Costa Miguel Journal: Eur Arch Otorhinolaryngol Date: 2018-03-29 Impact factor: 2.503
Authors: Federica Francescangeli; Maria Laura De Angelis; Rachele Rossi; Giovanni Sette; Adriana Eramo; Alessandra Boe; Ombretta Guardiola; Tao Tang; Shi-Cang Yu; Gabriella Minchiotti; Ann Zeuner Journal: Front Oncol Date: 2022-06-02 Impact factor: 5.738